Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer

NCT00117286 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Degarelix

Sponsor

Ferring Pharmaceuticals